Retatrutide Linked to Arrhythmias, Cardio Risks — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly disclosed safety and tolerability findings for its obesity drug retatrutide at the American Diabetes Association annual meeting and in the Lancet.
- Retatrutide was evaluated in the late‑stage TRANSCEND‑T2D‑1 study, where participants with diabetes achieved significant weight loss and blood‑sugar reduction.
- Arrhythmias occurred in 7 of 403 participants receiving retatrutide, while none were reported in the placebo arm.
- Major cardiovascular complications were observed in 3 participants treated with retatrutide, compared with zero events in the placebo group.
Why it matters: Patients with diabetes using retatrutide have increased cardiac risk, and Eli Lilly faces tighter regulatory scrutiny and slower market launch. Safety concerns also impact investor confidence and pricing strategies.
Ask SkimNews
